Aimee Jackson, PhDChief Scientific Officer at Atalanta Therapeutics
Aimee Jackson, PhD, Chief Scientific Officer, Atalanta Therapeutics Aimee has worked in the field of RNA interference and oligonucleotide therapeutics for >20 years. Aimee most recently served as the Vice President of Research for miRagen Therapeutics, where she advanced 3 microRNA programs from initial concept to First-in-Human clinical trials in less than 5 years. These programs encompassed diverse therapeutic areas and comprised both microRNA mimics and inhibitors. All three programs successfully completed Phase 1 clinical trials, and two of these programs have advanced to Phase 2 clinical trials, including a fibrosis program for which Aimee served as the Product Development Team Lead. Prior to joining miRagen, she led preclinical research at Regulus Therapeutics and Merck/Rosetta, where she served as Molecular Profiling Lead for the development of siRNA-based therapeutics. Known for identifying siRNA off-target effects, she played a lead role in the identification of siRNA design and chemistry aspects for enhanced activity and specificity.
Aimee is known for being passionate about cutting-edge and innovative approaches to technology and medicine to improve patients’ lives.
A Novel Approach to Improved Distribution, Durability, and Potency of RNAi across the CNS, 10:45amView Session